119 results
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
10 May 24
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:17am
are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
Section 102(b)(7), including, without limitation, the ability to attract and retain key officers and the potential to reduce litigation costs … litigation costs associated with frivolous lawsuits, we propose to adopt Article X so that it would state in its entirety as follows:
“ARTICLE X
8-K
EX-4.1
82ge24ydo31x8
18 Mar 24
Unregistered Sales of Equity Securities
4:31pm
8-K
0z9tubbg gopyr
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-1.1
444isn8 aig
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
8-K
p0qeq92iw e61pt
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.2
aeb7oh1mw634far 6um8
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
3a3eo8h3 94gf
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
0seinzc
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
7sos9mjj
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
t84vlv9
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
j0p0kz0991j7bdzo3mj
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
ou8f hti9
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
wpb 6jeua
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.2
r505dg
10 Oct 23
Regulation FD Disclosure
8:04am